Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : FDA : J&J Unit Recalls Potentially Flammable Bone Putty

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2012 | 12:13am CEST
   By Ben Fox Rubin 
 

The Food and Drug Administration said Johnson & Johnson (JNJ) unit Synthes last month initiated a recall on certain lots of bone putty, saying the medical product could catch fire during surgery.

The FDA gave the recall a Class I designation, its most serious type of recall.

The regulator said Synthes in early July issued a medical device recall letter, asking medical facilities to examine their inventories and immediately stop using specific lots of the putty. The product, called a hemostatic bone putty, is used to stop bone bleeding by creating a physical barrier along the edges of bones that have been damaged by trauma or cut during surgery.

The FDA said the putty could ignite under some conditions if contacted with certain surgical equipment.

The lots recalled were manufactured between July 6, 2011, and Dec. 14, 2011, and were distributed from Dec. 22, 2011, to June 25, 2012.

J&J in June completed its $19.7 billion purchase of medical-device maker Synthes. The health-care giant has worked to tackle a range of problem products, such as the bottles of children's Tylenol and other popular over-the-counter medicines, as well as some contact lenses and certain hip implants, that the company recalled due to manufacturing problems.

The company's shares closed Tuesday at $67.78 and were up 15 cents after hours. The stock is up 3.4% so far this year.

Write to Ben Fox Rubin at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
03:06p JOHNSON & JOHNSON : Research Shows That Canadian Military Servicemembers, First ..
01:38p JOHNSON & JOHNSON : Leaders Make Fortune's 2017 Most Powerful Women List
09/21 HEPATITIS C : Another "Child" of the Drug Industry, Says Ohio's Yes on Issue 2 C..
09/21 JOHNSON & JOHNSON : Research Shows That Canadian Military Servicemembers and Fir..
09/21 PFIZER : Goes to Court to Allow Competition for Biologics, Expand Options for Pa..
09/21DJPFIZER : Files Antitrust Lawsuit Against J&J -- WSJ
09/21 SELL JOHNSON & JOHNSON BECAUSE OF IT : Goldman
09/21 PFIZER : sues J&J for violating US antitrust laws
09/21 PFIZER : files lawsuit against Johnson & Johnson over biosimilar Inflectra
09/20DJPFIZER : Alleges J&J Thwarted Competition to Remicade, in Legal Test of Biotech-..
More news
News from SeekingAlpha
09:34a REDHILL BIOPHARMA : Highly De-Risked And Undervalued With A Deep Pipeline
08:00a 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 22, 2017
05:00a Johnson & Johnson Acquires Sightbox For Contact Lens Subscriptions
09/21 FDA's Woodcock says clinical trials system "broken"
09/21 Medical Devices Are The Quiet Growth Sector
Financials ($)
Sales 2017 75 834 M
EBIT 2017 22 814 M
Net income 2017 16 691 M
Debt 2017 16 470 M
Yield 2017 2,54%
P/E ratio 2017 21,47
P/E ratio 2018 17,84
EV / Sales 2017 4,88x
EV / Sales 2018 4,53x
Capitalization 354 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 137 $
Spread / Average Target 3,7%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.63%353 617
NOVARTIS11.88%223 850
ROCHE HOLDING LTD.6.19%221 926
PFIZER10.81%214 206
MERCK AND COMPANY11.75%178 914
SANOFI9.06%126 655